4C Medical Technologies Completes $35 Million Series C Financing And Appoints Saravana Kumar As President And Ceo
4C Medical Technologies Completes $35 Million Series C Financing And Appoints Saravana Kumar As President And Ceo
03/31/22, 8:00 AM
Location
minneapolisMoney raised
$35 million
Round Type
series c
4C Medical Technologies, Inc. ("4C Medical" or the "Company"), a privately-held medical technology company focused on the development of minimally invasive therapies for structural heart disease, announced that it has completed a $35.4 million Series C Preferred Stock financing. The Series C round was led by MicroPort CardioFlow Medtech Corporation (HKEX:2160).
Company Info
Location
minneapolis, minnesota, united states
Additional Info
4C Medical is a medical device company developing minimally invasive technologies for structural heart disease, focusing initially on mitral regurgitation (MR) therapy and subsequently on tricuspid regurgitation therapy. Subject to regulatory approvals, the Company's AltaValve® would be the first MR treatment with atrial-only fixation that is designed to minimize known issues associated with current TMVR technologies, which rely on placement and fixation within the native mitral annulus.